ANDRANIK AVAKIAN: Open Payments
NPI 1528599982 · CLOVIS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,466 in 158 payments from 16 companies in 2025. Trend: 2023 $1,578 · 2024 $1,969 · 2025 $2,466
Food & beverage: $2,466
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 33 | $478 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $466 |
| ABBVIE INC. | 30 | $246 |
| Alkermes, Inc. | 13 | $234 |
| Lundbeck LLC | 7 | $215 |
| Axsome Therapeutics, Inc. | 14 | $213 |
| Teva Pharmaceuticals USA, Inc. | 6 | $135 |
| Vanda Pharmaceuticals Inc. | 5 | $117 |
| Supernus Pharmaceuticals, Inc. | 4 | $88 |
| E.R. Squibb & Sons, L.L.C. | 3 | $70 |
Products named: REXULTI, CAPLYTA, VRAYLAR, ARISTADA, Auvelity, AUSTEDO XR, Qelbree, COBENFY.
Industry payments across CA — which companies pay providers there.
